{"product_id":"sarcopenia-isbn-9781119597872","title":"Sarcopenia","description":"\u003cb\u003eSARCOPENIA\u003c\/b\u003e \u003cp\u003e\u003cb\u003eAn in-depth examination of sarcopenia’s underexplored yet widespread impact within the field of gerontology\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eSarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.\u003c\/p\u003e\u003cp\u003eThis second edition of \u003ci\u003eSarcopenia\u003c\/i\u003e provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia’s biomarkers and its impact on the healthcare economy. This important text: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDefines sarcopenia and explains its clinical relevance\u003c\/li\u003e\n\u003cli\u003eCovers all recent scientific evidence\u003c\/li\u003e\n\u003cli\u003eOutlines treatment options\u003c\/li\u003e\n\u003cli\u003eConsiders prevention strategies\u003c\/li\u003e\n\u003cli\u003eDiscusses sarcopenia as a public health priority\u003c\/li\u003e\n\u003cli\u003eFeatures eight new chapters covering topics such as sarcopenia’s clinical management, its biomarkers, and its financial impact \u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eContaining vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, \u003ci\u003eSarcopenia\u003c\/i\u003e, second edition, is a groundbreaking and essential new resource.Tiefgehende Analyse von Sarkopenie in der Gerontologie. Die Erkrankung ist noch immer wenig erforscht, hat jedoch weitreichende Auswirkungen in dem Fachgebiet.\u003cbr\u003e \u003cbr\u003e Von Sarkopenie sind ältere Männer und Frauen betroffen. Im klinischen Kontext spielt die Krankheit, die erst 2016 formal in die Internationale Klassifikation von Krankheiten aufgenommen wurde, weiterhin eine ungeordnete Rolle. Die gesundheitlichen und finanziellen Folgen können für eine Gesellschaft immens sein, wenn keine einheitlichen und effektiven Verfahren umgesetzt werden, um die Erkrankung zu erkennen und zu behandeln.\u003cbr\u003e \u003cbr\u003e In der überarbeiteten und erweiterten 2. Auflage von Sarcopenia erhalten Geriatern und weitere Experten aus dem Gesundheitssektor einen Überblick über diese kaum erforschte und wenig erkannte Erkrankung. Die Herausgeber sind namhafte Experten und betrachten die Epidemiologie und Diagnose der Sarkopenie, Behandlungsoptionen und mögliche Präventionsstrategien. Die acht neuen Kapitel bauen auf dem vorhandenen Wissensstand auf und liefern neue Erkenntnisse, u. a. zu Biomarkern bei Sakropenie und den Auswirkungen auf das Gesundheitswesen. Diese wichtige Publikation\u003cbr\u003e \u003cbr\u003e - definiert Sarkopenie und erläutert die klinische Relevanz.\u003cbr\u003e - präsentiert die jüngsten wissenschaftlichen Erkenntnisse.\u003cbr\u003e - beleuchtet Behandlungsoptionen.\u003cbr\u003e - erläutert Präventionsstrategien.\u003cbr\u003e - zeigt die Bedeutung von Sarkopenie im Gesundheitswesen.\u003cbr\u003e - enthält acht neue Kapitel, u. a. zu dem klinischen Management der Erkrankung, zu Biomarkern und zu den finanziellen Folgen.\u003cbr\u003e \u003cbr\u003e Die 2. Auflage von Sarcopenia ist ein bahnbrechendes und wichtiges neues Referenzwerk für Kliniker und weitere Experten in der Geriatrie, Altenpflege und Altenheimen und der Fachrichtungen Ernährung, Onkologie, Endokrinologie, Chirurgie, Sportmedizin sowie einer Vielzahl von Fachgebieten.\u003cbr\u003e \u003c\/p\u003e\u003cp\u003eList of Contributors vii\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e1 Definitions of Sarcopenia 1\u003cbr\u003e\u003ci\u003eAlfonso J. Cruz‐Jentoft, Beatriz Montero‐Errasquin and John E. Morley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Epidemiology of Muscle Mass Loss with Age 11\u003cbr\u003e\u003ci\u003eMarjolein Visser\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 The Role of Mitochondria in Age‐Related Sarcopenia 19\u003cbr\u003e\u003ci\u003eLuigi Ferrucci, Marta Zampino, Paul Coen and Bret H. Goodpaster\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Motor Unit Remodeling 35\u003cbr\u003e\u003ci\u003eBen Kirk and Mathew Piasecki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Nutrition, Protein Turnover and Muscle Mass 45\u003cbr\u003e\u003ci\u003eSt\u003c\/i\u003e\u003ci\u003eéphane Walrand, Christelle Guillet and Yves Boirie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Recognizing Persons at Risk for Sarcopenia 63\u003cbr\u003e\u003ci\u003eJohn E. Morley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Adverse Outcomes and Functional Consequences of Sarcopenia 71\u003cbr\u003e\u003ci\u003eJean Woo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 A Lifecourse Approach to Sarcopenia 77\u003cbr\u003e\u003ci\u003eRichard Dodds and Avan Aihie Sayer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Acute Sarcopenia 95\u003cbr\u003e\u003ci\u003eBeatrice Gasperini, Stefano Volpato and Antonio Cherubini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Sarcopenia, Frailty, and Intrinsic Capacity 115\u003cbr\u003e\u003ci\u003eJurgen M. Bauer and Cornel Sieber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Osteosarcopenia 127\u003cbr\u003e\u003ci\u003eBen Kirk, Jesse Zanker, Steven Phu and Gustavo Duque\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Sarcopenic Obesity 147\u003cbr\u003e\u003ci\u003eMauro Zamboni, Federica Macchi, Nicole Nori and Andrea P. Rossi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Sarcopenia and Cognitive Impairment 157\u003cbr\u003e\u003ci\u003eLiang‐Kung Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Sarcopenia and Other Chronic Organ Diseases 175\u003cbr\u003e\u003ci\u003eHidenori Arai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Imaging of Skeletal Muscle 185\u003cbr\u003e\u003ci\u003eThomas F. Lang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Measurements of Muscle Mass, Equations and Cut‐off Points 199\u003cbr\u003e\u003ci\u003eMarjolein Visser and Laura Schaap\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Deuterated Creatine Dilution to Assess Muscle Mass (D3‐Cr Muscle Mass) in Humans: Methods, Early Results, and Future Directions 227\u003cbr\u003e\u003ci\u003ePeggy M. Cawthon and William J. Evans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Measurement of Muscle Strength and Power 239\u003cbr\u003e\u003ci\u003eMichael Drey, Sandra Helmers and J\u003c\/i\u003e\u003ci\u003eürgen M. Bauer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Measurements of Physical Performance 253\u003cbr\u003e\u003ci\u003eLaura Orlandini, Yves Rolland and Matteo Cesari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Biomarkers for Physical Frailty and Sarcopenia: A “Two‐Body Problem” 271\u003cbr\u003e\u003ci\u003eAnna Picca, Riccardo Calvani and Emanuele Marzetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Quality of Life and Sarcopenia 279\u003cbr\u003e\u003ci\u003eCharlotte Beaudart, Jean‐Yves Reginster, Olivier Bruy\u003c\/i\u003e\u003ci\u003eère and Anton Geerinck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Exercise Interventions to Prevent and Improve Sarcopenia 305\u003cbr\u003e\u003ci\u003eMark D. Peterson and Jose A. Serra\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Nutritional Approaches to Treat Sarcopenia 335\u003cbr\u003e\u003ci\u003eTommy Cederholm, Jurgen M. Bauer and Alfonso J. Cruz‐Jentoft\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Beta‐hydroxy‐beta‐methylbutyrate (HMB) and Sarcopenia 355\u003cbr\u003e\u003ci\u003eFrancesco Landi, Riccardo Calvani, Anna Picca and Emanuele Marzetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 The Future of Drug Treatments 367\u003cbr\u003e\u003ci\u003eFrancesco Landi, Graziano Onder and Rolland Yves\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Sarcopenia: Is It Preventable? 403\u003cbr\u003e\u003ci\u003eStany Perkisas, Keliane Liberman, Ivan Bautmans and Maurits Vandewoude\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Financial Impact of Sarcopenia 421\u003cbr\u003e\u003ci\u003eKristina Norman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Sarcopenia Management for Clinicians 433\u003cbr\u003e\u003ci\u003eRenuka Visvanathan and Solomon Yu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 441\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAlfonso J. Cruz-Jentoft, MD,\u003c\/b\u003e Professor, Geriatrics, Universidad Europea de Madrid, and Director of Geriatric Medicine, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eJohn E. Morley, MD,\u003c\/b\u003e Professor, Geriatrics, St Louis University Medical School, St Louis, MO, USA.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAn in-depth examination of sarcopenia's underexplored yet widespread impact within the field of gerontology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.\u003c\/p\u003e \u003cp\u003eThis second edition of \u003ci\u003eSarcopenia\u003c\/i\u003e provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia's biomarkers and its impact on the healthcare economy. This important text:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eDefines sarcopenia and explains its clinical relevance\u003c\/li\u003e \u003cli\u003eCovers all recent scientific evidence\u003c\/li\u003e \u003cli\u003eOutlines treatment options\u003c\/li\u003e \u003cli\u003eConsiders prevention strategies\u003c\/li\u003e \u003cli\u003eDiscusses sarcopenia as a public health priority\u003c\/li\u003e \u003cli\u003eFeatures eight new chapters covering topics such as sarcopenia’s clinical management, its biomarkers, and its financial impact\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eContaining vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, \u003ci\u003eSarcopenia\u003c\/i\u003e, second edition, is a groundbreaking and essential new resource.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989987803365,"sku":"NP9781119597872","price":172.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119597872.jpg?v=1761786117","url":"https:\/\/k12savings.com\/products\/sarcopenia-isbn-9781119597872","provider":"K12savings","version":"1.0","type":"link"}